Mogam Biotechnology Research Institute Patent applications |
Patent application number | Title | Published |
20150231220 | EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF - The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands. | 08-20-2015 |
20150111282 | HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME - Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus. | 04-23-2015 |
20140147458 | NOVEL VARICELLA-ZOSTER VIRUS STRAINS, AND CHICKEN POX AND HERPES ZOSTER VIRUS VACCINE USING SAME - The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient. | 05-29-2014 |
20130259886 | BROADLY PROTECTIVE INFLUENZA T-CELL VACCINE AGAINST DIVERSE INFLUENZA A VIRUSES - There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses. | 10-03-2013 |
20130065952 | TUMOR-SPECIFIC PROMOTER AND ONCOLYTIC VIRUS VECTOR COMPRISING THE SAME - Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer. | 03-14-2013 |
20130058897 | HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME - Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus. | 03-07-2013 |
20120282687 | EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc. | 11-08-2012 |
20120282686 | EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc. | 11-08-2012 |
20120282685 | EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc. | 11-08-2012 |
20120237921 | FULL GENOME DNA OF HUMAN CYTOMEGALOVIRUS STRAIN JHC ISOLATED FROM KOREAN PATIENT AND OPEN READING FRAMES THEREOF - Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFS) thereof and, more particularly, UL1, UL119 and RL6. | 09-20-2012 |
20110129872 | METHOD FOR A PRODUCTION OF A RECOMBINANT PROTEIN USING YEAST CO-EXPRESSION SYSTEM - The present invention relates to a method for mass production of a recombinant protein comprising the step of culturing a yeast transformed with: a recombinant gene construct comprising a yeast promoter, a gene coding a signal sequence and a gene coding a target protein; and also with one or more genes coding folding accessory protein selected from the group consisting of PDI1 (protein disulfide isomerase 1), SEC23 (secretory 23), TRX2 (thioredoxin 2) AHA1 (activator of heat shock protein 90 ATPase), and SCJ1 ( | 06-02-2011 |
20110045584 | EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc. | 02-24-2011 |
20110008885 | LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES - A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA. | 01-13-2011 |
20100239657 | COMPOSITE FOR LIVER-SPECIFIC DELIVERY AND RELEASE OF THERAPEUTIC NUCLEIC ACIDS OR DRUGS - The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents. | 09-23-2010 |
20100209491 | METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV - A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided. | 08-19-2010 |
20100196370 | FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT - The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor. | 08-05-2010 |
20100184136 | Methods For Enhancing A Secretion Efficiency Of Recombinant Foreign Protein In Yeast Expression System - Provided is a method for improving secretion efficiency of a recombinant foreign protein in a yeast expression system. The method comprises transforming a yeast host with a recombinant foreign gene construct comprising a galactose-inducible promoter, a secretion signal sequence and a gene encoding the foreign protein to construct a transformed yeast strain; and culturing the transformed yeast strain under the condition that the activity of the galactose-inducible promoter is controlled. Improved secretion efficiency of the foreign protein can be achieved by decreasing over-expression-induced insoluble precipitation of the recombinant foreign protein suffered by a conventional galactose-inducible promoter-based yeast expression system, via appropriate control of a level of galactose functioning as an inducer of the galactose-inducible promoter in cells. Due to improved secretion efficiency of the recombinant foreign protein, present invention makes a contribution to improvement in productivity of recombinant foreign proteins in the yeast expression system and reduction in production costs. | 07-22-2010 |
20100063132 | SMALL INTERFERING RNA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS B COMPRISING THE SAME - The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention. | 03-11-2010 |
20100003742 | METHOD FOR REDUCING FUCOSE CONTENTS OF RECOMBINANT PROTEINS - The present invention relates to a method for reducing the fucose content of a recombinant protein, which comprises expressing in an animal cell the recombinant protein and FUCA1, an FUCA1 mutant, FUCA2, or a fragment of FUT8 localization domain; or with a fusion protein of a fragment of FUT8 localization domain and a fragment of FUCA1, a FUCA1 mutant or FUCA2. Therefore, the antibody expressed according to the method of the present invention exhibits a reduced fucose content in their Fc regions, which leads to the improvement in the therapeutic effect thereof. | 01-07-2010 |
20090318531 | Small Interfering RNA Specific For HCV And Therapeutic Agent For Hepatitis C Comprising The Same - The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV protein expression and replication. The method of the invention, which includes the step of administrating the synthetic siRNA or a DNA vector encoding the RNA, is thus effective for the treatment of HCV carrier by inhibiting HCV gene expression and replication. | 12-24-2009 |
20090162317 | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same - There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same. | 06-25-2009 |
20080200657 | Mutant of Granulocyte-Colony Stimulating Factor (G-Csf) and Chemically Conjugated Polypeptide Thereof - Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (Gly) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity. | 08-21-2008 |